CLOs on the Move

Biosplice Therapeutics

www.biosplice.com

 
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.biosplice.com
  • 9360 Towne Centre Drive
    San Diego, CA USA 92121
  • Phone: 858.926.2900

Executives

Name Title Contact Details

Similar Companies

Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world`s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

Verdezyne

Verdezyne, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Spectrex Corp

Spectrex Corp is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Redpin Therapeutics

Welcome to Redpin Therapeutics. We are a privately held, preclinical stage gene therapy company based in New York City. We are developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Our approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy.

Gossamer Bio

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio`s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need,